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ABSTRACT 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder marked by progressive 
impairment of cognitive ability. Patients with AD display neuropathological lesions 
including plaques, neurofibrillary tangles, and neuronal loss in brain regions linked to 
cognitive functions. Despite progress in uncovering many of the factors that contribute 
to the etiology of this disease, the cause of neuronal death is largely unknown. 
Neuroinflammation seems to play a critical role in the pathogenesis of AD. 
Inflammatory processes in the brain are mainly mediated by the intrinsic innate immune 
system consisting of astrocytes and microglial cells, and cytokine, chemokine, and 
growth factor signaling molecules. However mounting evidence suggest that the Central 
Nervous System (CNS) is accessible to lymphocytes and monocytes from the blood 
stream, indicating that there is an intense crosstalk between the immune and the CN 
systems. On the other hand some AD-specific brain-derived proteins or metabolites may 
enter the plasma through a deficient blood-brain barrier, and exert some measurable 
signaling properties in peripheral cells. The goals of this review are: 1) to explore the 
evidences of changes in signaling pathways that could mediate both central and 
peripheral manifestations of AD, and 2) to explore whether changes in immune cells, 
particularly lymphocytes, could contribute to AD pathogenesis. 
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Introduction 
 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder with a 
prevalence of 11% in people age 65 and older and represents 60% of all cases of 
dementia [1]. It begins with a decline in cognition followed by a number of other 
changes in brain functioning, including impairments in language and visual-spatial 
skills, and disorientation. This impairment in cognitive functions is due to anatomical 
atrophy of AD brains, which correlates with severe neuronal loss. Neuropathological 
hallmarks are extracellular deposits of misfolded amyloid-! (A!) protein, so-called 
senile plaques and intracellular accumulations of hyperphosphorylated microtubule-
associated tau (neurofibrillary tangles, NFT). Although the molecular mechanisms of 
AD are still being unraveled, neuroinflammation has been reported to contribute to the 
pathophysiology of AD and late-onset neurodegenerative diseases [2]. Local immune 
responses involving glial cells and the complement system are activated in the AD brain 
[3; 4]. The cells responsible for the inflammatory reaction are microglia, astrocytes and 
neurons. These activated cells produce high levels of inflammatory mediators such as 
proinflammatory cytokines and chemokines, prostaglandins, leukotrienes, 
thromboxanes, coagulation factors, free radicals as reactive oxygen species and nitric 
oxide, complement factors, proteases and protease inhibitors, and C-reactive protein [5]. 
In addition, there is now strong evidence suggesting the involvement of a systemic 
immune response in AD [6]. Both increased concentrations of proinflammatory 
cytokines and changes in lymphocyte subsets, with an augmented percentage of 
immune cells expressing activation markers, are described in AD [7-9]. Thus, it seems 
that the brain and immune system are intricately connected and involved in significant 
crosstalk to maintain homeostasis. 
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The communication pathways from peripheral sites of inflammation to the brain have 
been investigated in animal models [10]. It was reported that systemically generated 
inflammatory mediators signal to the brain via both neural and humoral routes in the 
blood [11; 12]. Cytokines such as interleukin-6 (IL-6), IL-1!, and tumor necrosis factor 
(TNF) circulate in the blood and signal to the CNS via the circumventricular organs, 
which lack a patent blood-brain barrier (BBB) [13] or signal across the BBB via 
receptors expressed on the endothelium [14]. The presence of multiple pathways from 
the peripheral immune system to the brain highlights the importance of this signaling 
process. On the other hand, some AD-specific brain-derived proteins or metabolites 
may enter in the plasma through a deficient BBB, and exert some measurable signaling 
properties [15]. Indeed, significant changes in gene expression or at posttranscriptional 
level have been reported in freshly isolated peripheral blood mononuclear cells 
(PBMCs) from AD patients and non-demented controls [16-18]. Whether the systemic 
alterations represent a cause or consequence of the neurodegenerative process is still a 
controversial issue.  
In this review we will summarize current knowledge of changes in signaling pathways 
in lymphocytes from AD patients and discuss the significance of changes in peripheral 
cells in AD pathogenesis.  
Altered signaling pathways in AD lymphocytes 
The concept of PBMCs as a “window” into the CNS was first proposed by Percy et al., 
in their comprehensive review of peripheral manifestations of AD [19]. Lymphocytes 
represent a useful material, easily accessible to study the biochemistry and molecular 
biology of the CNS and for investigating possible systemic derangements in 
neurodegenerative disorders. Based on this assumption, PBMCs have been widely used 
by several laboratories as an experimental model to investigate receptor signal 
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transduction alterations searching for emerging biomarkers at peripheral level to 
implement the strategies for diagnostic and/or therapeutic approach in AD.  
Expression profiling of PBMCs has disclosed dysfunction of pathways subserving 
signal transduction, lipid metabolism, mitochondrial bioenergetics, intracellular 
trafficking, proteasomal activity, and cell survival [16; 17; 20]. Among others, abnormal 
amyloid precursor protein (APP) expression, altered levels of antioxidant enzymes, 
oxidative damage to DNA, RNA and protein, deregulated cytokine secretion and 
augmented rates of apoptosis are features shared by AD brain and lymphocytes [18].  
Moreover, lymphocytes express N-methyl-D-aspartate (NMDA), dopamine and 
acetylcholine receptors [21-23] thought to function primarily in the CNS. Therefore, in 
addition to classical immunological stimuli such as antigens, cytokines, chemokines and 
growth factors, they can be activated by neurotransmitters. 
Here, we will focus on altered control of cell cycle and apoptosis, mitochondrial 
dysfunction, and changes in the proteasome activity as peripheral markers for detection 
of AD in lymphocytes. 
Cell cycle control failure in AD lymphocytes 
Increasing evidence suggest that neuronal cell cycle events underlie neurodegeneration. 
It is thought that in AD susceptible neurons re-enter an aberrant cell cycle, but since 
they cannot complete the cell cycle, they die [24-27]. Cell cycle re-entry appears to 
represent an early and critical event in AD, leading to the development of AD-related 
pathology such as hyperphosphorylation of tau and A! deposition and ultimately 
inducing neuronal cell death [28; 29]. Several factors, including many of the identified 
risk factors for Alzheimer's disease, such as elevated plasma homocysteine levels, 
ageing, menopause, low thyroid levels, low level prolonged oxidative stress or head 
injury, can either represent mitogenic signaling for neurons or facilitate cell cycle re-
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entry in vulnerable neuronal populations [30]. On the other hand, the APP and A! have 
mitogenic properties in vitro, and accumulation of growth factors have been found in 
diffuse amyloid deposits [31]. The rapid response of microglia and astrocytes to any 
disturbance in the CNS microenvironment results in an increased expression of specific 
cell surface receptors, and in the release of growth factors and cytokines, which may be 
protective acutely but, if not resolved, may contribute to cell cycle activation in 
vulnerable neurons. In addition and because of failure of BBB in AD [32], growth 
factors and cytokines can eventually activate the immune cells. Indeed cell cycle 
deregulation has been found in peripheral cells from AD patients such as lymphocytes 
and fibroblasts [33-39]. Similar to that described in AD brain, the G1/S transition 
control mechanism fail in lymphocytes from AD subjects. In a early work by Nagy 
group, aimed specifically at the detection of any defects of the G1/S transition control, 
[35] was reported a significant reduction on the relative lengthening of the G1 phase in 
response to cell cycle inhibitors in AD lymphocytes. Interestingly, the relative 
lengthening of the G1 phase distinguish lymphocytes from sporadic or familial AD 
patients [40]. In consonance with the idea that cell cycle disturbances are early 
pathogenic events in AD brain, the G1/S control failure has been also detected in 
lymphocytes from Mild Cognitive Impairment (MCI) patients, a prodromal stage of AD 
[35; 38].  
During the beginning of the cell cycle at the G1 phase, a variety of growth signals 
induce changes in cell cycle regulatory proteins. The G1/S transition is regulated by 
cyclin D, and E proteins, cyclin-dependent kinases (CDKs) CDK4/6, and cyclin-
dependent kinases inhibitors (CDKIs) [41]. Cyclin D forms an active complex with its 
catalytic subunits CDK4/6-CDKs resulting in the phosphorylation and activation of the 
retinoblastoma protein (pRb) complexes to E2F1-DP1. Transcription factor E2F1 is 
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almost exclusively localized in the nucleus and when co-expressed with its DNA-
binding partner, DP1, it relocates from the cytoplasm to the nucleus forming activated 
E2F1-DP1 complex [42]. Protein complex pRb-E2F1-DP1 is a major regulator of the 
G0/G1-to-S-Phase transition. Initial phosphorylation of pRb-E2F1-DP1 facilitated by 
complex cyclin D/CDK4/6 results in gene transcription of cyclin E. Cyclin E then binds 
to its catalytic subunit CDK2 forming active complex cyclin E/CDK2 which 
hyperphosphorylates pRb in the pRb-E2F1-DP1 complex. Hyperphosphorylation of 
pRb causes disassociation and full activation of E2F1-DP1, thus allowing binding to 
and activation of E2F response elements in promoters of S-Phase cell cycle proteins. In 
addition CDKIs either from the CIP/KIP1 (p21 and p27) or the INK families  (p16 and 
p18) play a predominant role in controlling the G1/S transition [43]. Evidences for 
changes in the expression levels of these cell cycle regulatory proteins in AD brain have 
been long recognized [24; 44]. Enhanced levels of phosphorylated pRb were found in 
AD [45; 46], and altered subcellular localization of the transcription factor E2F-1 was 
reported in AD brain [45; 47]. Several groups have described similar changes in cell 
cycle regulatory proteins in lymphocytes from late-onset AD. They are summarized in 
Table 1. 
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TABLE 1 
 
Changes in cell cycle regulatory proteins in lymphocytes from late-onset 
Alzheimer’s disease patients. 
 
 
Protein    Role              Change  Reference 
 
 
Cyclin D  G0/G1 late G1/S               !  [40] 
Cyclin E  G1 to G1/S               !  [39]  
          
CDK2   Late G1/S               !  [39] 
CDK4   G1/S                !  [17] 
 
p21   Multi cyclin/CDK inhibitor              !"  [33; 40; 48] 
p27   Cyclin D and E/CDK inhibitor              "  [34; 39; 49] 
p16   CDK4/CDK6 inhibitor               !  [17] 
 
pRb family of proteins CDK2/4/6 check point               !  [34; 39; 50] 
 
E2F   Transcriptional activator of  
                                           S-phase specific genes   !  [39; 50] 
NF-!B   Transcriptional activator of cyclin D1  !"  [50; 51] 
p53   Transcriptional activator of p21  !  [38; 40; 52] 
 
 
While it is clear that failure of regulation of cell cycle occurs in neurons and peripheral 
cells in AD, the signaling pathways that trigger these events are not well defined. The 
same or similar mitogenic signals in both brain and lymphocytes might alter cell cycle 
activity by activation of growth factor receptors or their signaling molecules (kinases or 
transcription factors).  
Previous work from this laboratory aimed at studying the underlying signaling 
pathways involved in the enhanced proliferation of immortalized lymphocytes from AD 
patients [34; 49; 53; 54]. We investigated the effects of perturbing receptor signaling 
pathways by using inhibitors of protein-kinases or calmodulin  (CaM), as well as 
pertussis toxin, on the proliferation of normal and AD lymphoblasts. We demonstrated 
that Ca2+/CaM signaling was overactivated in AD cells, as CaM antagonist were able to 
restore normal rates of cell proliferation [34; 54]. Increased activity of the Na+/H+ 
exchange and transcriptional alterations of E2F and NF-"B (nuclear factor kappa-light-
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chain-enhancer of activated B cells) found in AD cells were also sensitive to CaM 
antagonists [50; 54]. Increased proliferation of AD lymphoblasts was causally linked to 
decreased levels of the CDK inhibitor p27 and enhanced phosphorylation of pRb 
protein [34; 49; 53]. Moreover, we reported that Ca2+/CaM-dependent overactivation of 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt signaling cascade in AD 
cells, plays an important role in regulating p27 abundance by increasing its degradation 
in the ubiquitin-proteasome pathway [53]. Half-life of p27 protein was markedly 
reduced in lymphoblasts from AD patients compared with that in control cells. Our 
results indicated that the increased phosphorylation of p27 at Thr187, rather than 
changes in the 26S proteasome activity, is likely responsible for the enhanced 
degradation of p27 in AD cells. It was suggested that overactivation of PI3K/Akt in AD 
cells somehow facilitates phosphorylation of Thr187 by the cyclin E/CDK2 complex. In 
addition, PI3K/Akt phosphorylates other p27 residues (Thr157, Thr159), which are 
important in controlling the nucleo-cytoplasmic traffic of p27 [55]. The exclusion of 
p27 from the nucleus would then facilitate its degradation by the proteasome [53; 56] 
and thus, relieving cyclin E/CDK2 kinase activity from p27 inhibition. 
The importance of PI3K/Akt signaling pathway in AD brain was put forward by 
previous reports that linked this cascade with amyloid-!, neurofibrillary tangles and 
neuronal loss in AD brain. Increased phospho-Akt (Ser473) has been detected in AD 
temporal cortex neurons [57]. Furthermore, overactivation of Akt in AD brains is 
accompanied by increased levels of phosphorylation of Akt substrates such as glycogen 
synthase kinase 3! (GSK3!), mammalian target of rapamycin (mTOR), tau and lower 
levels of p27 [57; 58].  
On the other hand, Ca2+/CaM overactivation of PI3K/Akt in AD lymphoblasts was 
associated with higher CaM content than in control cells [59]. It was suggested that the 
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increased CaM levels in AD cells synergize with serum to overactivate PI3K/Akt 
pathway. In agreement with previous reports [60; 61], we found that CaM is able to 
bind to the 85 KDa regulatory subunit of PI3K (p85). Moreover it was observed a 
significant higher binding of CaM to p85 in AD lymphoblasts compared to control cells, 
thereby resulting in enhanced Akt phosphorylation. 
The up-regulation of CaM levels in AD lymphoblasts is not the consequence of altered 
expression of any of the three different genes that encode CaM, but rather the result of 
decreased rates of CaM degradation [59]. It was shown that intracellular Ca2+ levels and 
reactive oxygen species (ROS) seem to control CaM degradation [59]. In AD cells, 
reducing the rate of degradation of CaM could be the cellular response to Ca2+ overload, 
since it is well documented higher levels of cytosolic free Ca2+ in lymphocytes from 
sporadic as well as familial AD patients [62-66]. 
A close association between alterations in Ca2+ homeostasis and cell cycle activity in 
AD cells was also found by other groups [67; 68]. In addition, Ca2+ dysfunction has 
been linked to changes in other cell survival signaling transduction processes. AD cells 
were shown to exhibit changes in the functioning of G proteins [69], activity of PKC 
[70; 71], and increased activity of IP3 receptor activity was reported in lymphocytes 
derived from familial AD patients [62; 72]. 
Signaling molecules downstream PI3K/Akt such mTOR or GSK3!, are altered in 
lymphocytes derived from AD patients [35; 73; 74]. mTOR is a highly conserved 
serine-threonine kinase that is essential for the co-ordination of intra and extra-cellular 
signals concerning cell growth, division and differentiation  [75]. In the central nervous 
system, the mTOR pathway is known to play a key role in regulating synaptic 
remodeling [76], as well as modulating autophagy activity in neurons [77]. The first 
evidence that mTOR signaling was altered in peripheral cells from AD patients was 
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reported by the Nagy’s laboratory [35]. They found that AD lymphocytes showed a 
reduced response to rapamycin when compared with control cells. Later on it was 
demonstrated that alterations in mTOR signaling were associated with cognitive decline 
in AD [78]. The examination of the functional integrity of mTOR signaling in AD 
lymphocytes by gene expression analysis revealed that the up- or down- regulated 
mTOR genes were significantly enriched for 25 molecular and cellular functions 
including cellular growth and proliferation, cell cycle, and the main metabolic pathways 
[79]. Interestingly it was suggested that the assessment of the functional integrity of the 
downstream signaling cascade of mTOR from lymphocytes may reflect susceptibility to 
develop AD rather than provide an assessment of disease state, and therefore could be 
exploited diagnostically [79]. 
GSK3! the key enzyme in the control of glycogen synthesis is also involved in the 
regulation of critical intracellular signaling pathways, including cell cycle, gene 
expression and apoptosis [80-82]. The disruption of GSK3! homeostasis has been 
linked with the development of several diseases including AD. GSK3! activity is 
increased within the AD brain, favoring the hyperphosphorylation of microtubule-
associated protein tau and the formation of neurofibrillary tangles [83]. Moreover, the 
activation of GSK3! inhibits the cleavage of the APP protein, increasing the production 
of the amyloid-! (A!42) peptide [84] and leads to memory impairment in animal 
models [85; 86]. Therefore, the deregulation of GSK3! activity has major effects in key 
pathological features of AD and therefore is widely considered a therapeutic target of 
interest. Altered regulation of GSK3! was also found in white blood cells and platelets 
from AD patients and MCI [73; 87]. These observations suggested that the peripheral 
determination of GSK3! activity might be a useful diagnostic biomarker for early AD 
and a surrogate marker of early pathophysiological changes.  
 12 
GSK3! activity is also modulated by other relevant extracellular signaling pathways 
besides the PI3K/Akt; they are the insulin/insulin-like growth factor I (IGF-I), or the 
canonical Wnt pathways [88]. 
There is widening recognition that AD is closely linked to a state of relative insulin 
resistance in the brain [89; 90]. Levels of IGF-I, insulin and cognate receptors are 
deregulated in AD brain [91]. In normal brain, IGF-I and insulin promote glucose 
utilization, energy metabolism and neuronal survival [92], largely through 
PI3K/Akt/GSK3! signaling [93]. Insulin receptors populate neuronal synapses and 
astrocytes in memory-processing brain regions [94]. Acute insulin treatment improved 
memory in both humans and rodents [95-97]. On the other hand, increased A! 
production prompts the onset of glucose intolerance and insulin resistance [98]. The 
insulin-induced activation of the PI3K/Akt/GSK3! is also blunted in peripheral ells 
from AD patients [99]. GSK3! plays a crucial role in the regulation of cell cycle events 
through its ability to phosphorylate !-catenin. Phosphorylated !-catenin is recognized 
by ubiquitin and targeted for proteasomal degradation [100]. Consequently, signals that 
modify GSK3! activity are expected to alter !-catenin levels.  In the nucleus, !-catenin 
interacts with transcription factors TCF (T-cell factor)/LEF (lymphoid enhancing factor) 
[101] to activate genes that allow cell cycle progression as cyclin D1 and c-myc [102]. 
On the other hand, GSK3! has been identified as an important regulator of 
inflammation [103] promoting the production of several pro-inflammatory cytokines 
such as IL-6, IL-1!, and TNF#, as well as decreasing the levels of the anti-inflammatory 
cytokine IL-10.  Data from Avila’s group demonstrated that GSK3! overexpression in 
neurons leads to the appearance of a unique pattern of cytokines in the brain in vivo that 
is detrimental for appropriate neuron maturation [80; 104]. 
 13 
GSK3! is a key transducer of the canonical Wnt signaling, the components of which are 
involved in AD [105]. In the canonical pathway, members of the Wnt family interact 
with Frizzled, a seven-transmembrane receptor, and with an additional receptor that 
corresponds to either low-density lipoprotein receptor-related protein 5 (LRP-5) or 
LRP-6. Activation of this pathway leads to the inhibition of GSK3! through a cascade 
of intracellular reactions that involve protein kinases and adaptor proteins [102]. 
Inestrosa and coworkers have provided evidences that Wnt pathway is modulated by A! 
in AD [106]. Moreover it has been suggested that Wnt pathway might play a role in the 
early induction of the cell cycle in neurons [107]. As far as we know, the role of Wnt 
signaling pathway on peripheral cells from AD patients has not been investigated.  
Impaired apoptosis in AD lymphocytes 
The molecular cascades leading to the loss of neuronal populations in AD have not been 
fully delineated. However it appears that apoptosis is the final fate of vulnerable 
neurons. Careful examination of brains after autopsy for signs of apoptosis has 
provided, compelling evidence that apoptosis is increased in AD brains compared with 
brains from non-demented [108]. Several markers of apoptosis, such as nuclear DNA 
fragmentation, and activation of caspases were reported to be elevated in AD brains 
[109; 110]. 
It is now widely accepted that an aberrant re-initiation of the cell cycle activation in 
vulnerable neurons is one important inducer of neuronal apoptosis [31; 111; 112]. There 
is a significant body of evidence pointing to a role for neuronal cell cycle proteins in the 
modulation of stress-induced apoptosis, including the neuroprotective effects shown by 
certain CDK inhibitors [113]. Neuronal apoptosis, however, differ of classical apoptosis 
in the long time taken for susceptible neurons to die. It appears that they are highly 
protected against rapid apoptotic cell death. Even if the apoptotic cascade is initiated, 
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the lack of the downstream caspases [114] leads to a long agony, instead of rapid 
apoptosis [115]. As a consequence, neurons survive for long periods of time in the G2 
phase of the cell cycle becoming more vulnerable to stress according to the “two-hit 
hypothesis” [116; 117]. The need of two hit for effective neuronal death provides an 
explanation for the low amounts of neuronal apoptosis in AD (less than one in 10,000 at 
any given time show signs of apoptosis) [118]. This apoptosis avoidance, together with 
differences in the signal transduction pathways activated by growth factors in the brain, 
may represent a defense program for susceptible neurons in AD, in analogy with 
neoplasia. Indeed some authors have considered AD pathology as an abortive neoplastic 
disorder [29]. Interestingly, lymphoblasts from sporadic AD patients show tumor-like 
features. Work from our laboratory demonstrated that compared with lymphoblasts 
from non-demented subjects, AD cells have a higher proliferative activity and increased 
resistance to apoptosis induced by serum deprivation [50; 119].  Selective impairment 
of mechanisms involved in cell death has been also reported in fibroblasts from AD 
patients. The protective mechanism of AD fibroblasts against H2O2 was related to an 
impairment of cell cycle arrest and a diminished induction of apoptosis [120]. 
Increased resistance of AD lymphoblasts to serum deprivation also depends on   
Ca2+/CaM signaling [50; 119]. Therefore, CaM seems to play a pivotal role in 
transmitting proliferative/survival signals from the plasma membrane to the nucleus. 
Whether CaM contributes to cell proliferation or apoptosis may depend on cellular CaM 
levels and/or activity, as well as the presence of growth-stimulatory signals. The lower 
vulnerability to death of AD cells was associated with decreased NF-"B DNA-binding 
activity [50] and higher levels of the CDK inhibitor p21 [48; 121]. The involvement of 
NF-"B activation in inducing apoptosis was previously reported in HEK 293 cells [122] 
and conversely inhibition of NF-"B was shown to prevent cell death induced by the 
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oncogenic protein, latent membrane protein 1 (LMP1) in Rat-1 cells [123]. Further 
work aimed at studying the molecular mechanism involved in the distinct Ca2+/CaM-
mediated regulation of survival of AD lymphoblasts revealed a CaM/CaMKII-
dependent downregulation of the ERK1/2 signaling pathway [119]. It is well known 
that the kinetics and duration of ERK1/2 activation are important factors in determining 
the cellular response [124; 125]. In lymphoblasts derived from AD patients we observed 
an enhanced and transient activation of ERK1/2 in AD lymphoblasts associated with 
increased proliferation, whereas serum starvation induced a sustained activation of 
ERKs, although lower than in control cells. These results are in consonance with 
previous work in which a persistent activation of ERK1/2 was associated with cell cycle 
arrest and apoptosis in different cell types [126-128].  
As already mentioned, the higher resistance of AD lymphoblasts to death induced by 
trophic factor deprivation was accompanied by increased levels of p21 [48]. Several 
reports pointed out that in addition to being an inhibitor of cell proliferation, p21 might 
protect cells from apoptosis [129]. For example, it has been reported that upregulation 
of p21 blocked the oxidative stress-induced death of human myeloma U266 cells [130] 
and rendered resistance to chemotherapy drugs in other types of cancer cells [131]. 
Thus the increase in p21 cellular content in AD may confer these cells a survival 
advantage.  The transcription of p21 was found to be upregulated in AD cells by the 
forkhead box O3a factor (FOXO3a). The reduced ERK1/2 activation of ERK1/2 
prevents the phosphorylation of FOX3a and subsequent translocation and degradation 
via a murine double minute (MDM2)-mediated ubiquitin proteasome pathway, thereby 
allowing the accumulation of this transcription factor in the nucleus [48]. In addition to 
the increased transcriptional activation of p21 gene observed in AD lymphoblasts, we 
also found an increase in the cytosolic content of p21 protein in AD cells. The 
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cytoplasmic p21 is thought to be a positive modulator of cell survival [43; 132]. 
Upregulation of p21 has also been associated with blockade of oxidative stress induced 
apoptosis in fibroblasts from AD patients [133].  
 Impairment of mechanisms involved in cell death was previously reported in peripheral 
cells from AD patients [120; 133-135] although there are conflicting results as to 
whether cells from AD patients are less or more vulnerable to situations that promote 
cell death. Most likely these discrepancies result from the different cell types and stress-
inducing conditions used. For example, in contrast with lower sensitivity to serum 
deprivation-induced death in AD lymphocytes, these cells appears to be more 
susceptible to oxidative stress-induced apoptosis [136-138]. The impaired apoptosis 
mediated by oxidative stress was even observed in MCI patients [137], although 
enhanced susceptibility to H2O2-induced death in peripheral lymphocytes correlates 
with dementia severity and enhanced death in AD patients is attributable to a Poly 
(ADP-ribosyl) polymerase-1 (PARP)-dependent increase in the apoptosis/necrosis ratio 
[138]. 
The other two important branches besides ERK1/2 of the Mitogen-activated protein 
kinases (MAPK) signaling, p38 and the c-Jun-N-terminal kinase (JNK), have also been 
associated to neuronal apoptosis in AD brain [130]. Impaired regulation of expression 
and activity of these two kinases have been documented in brain and cell models of AD 
[139; 140], and it has been reported that pharmacological modulation of p38/JNK 
activity attenuated neuronal cell death [141]. Recent work has reported that both 
phosphorylated p38 and phosphorylated JNK levels were significantly increased in 
lymphocytes from AD patients compared with healthy controls, in agreement with the 
increased expression of phosphorylated p38 and phosphorylated JNK in AD brains 
[142]. These authors found that phosphorylated p38 and JNK levels in AD lymphocytes 
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were positively correlated with disease duration and severity, suggesting the peripheral 
alteration of these two kinases is more a consequence of a CNS disease mechanism 
rather than being linked to casual mechanisms. It was suggested that determination of 
peripheral changes in the expression of the p38 and JNK could provide useful 
biomarkers of disease progression.  
Systemic alterations in mitochondrial dysfunction and in the proteasome activity 
Mitochondrial dysfunction and impairment of the ubiquitin-proteasome system (UPS) 
are important features of AD shared by the CNS and peripheral cells [143; 144]. 
Mitochondria are the main source of energy and the primary source of reactive oxygen 
species (ROS). Therefore, impairment of mitochondrial function leads to decreased 
energetic and increased production of free radicals that can in turn have an impact on 
cellular functions with consequent neuronal loss.  On the other hand, dysfunction of the 
UPS has been associated with the deposition of ubiquitinated protein aggregates [143] 
and widespread disruption of the proteostasis network. The UPS provides 80% to 90% 
of the proteolysis of the short-life proteins and ensures, as chaperon-molecules, the right 
conformation and hence the correct function of the proteins [145].  
Mitochondrial dysfunction has been documented in peripheral cells from AD patients. 
For example, it has been reported alterations in the electron transport chain activity in 
lymphocytes from AD patients [146]. Another study showed decreased mitochondrial 
membrane potential in AD lymphocytes, together with a reduced rate of respiration and 
a significant impairment of total oxidative phosphorylation (OXPHOS) capacity, 
suggesting mitochondrial uncoupling that led to a failure in the maintenance of cellular 
energetics [147]. 
Increased oxidative stress has been also described in lymphocytes from AD patients. 
The leakage of ROS from mitochondria can be detected by different parameters such as 
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the direct measurement of ROS levels, the antioxidant status or DNA oxidation. Many 
authors have found elevated levels of oxidative DNA damage and increased ROS levels 
in peripheral lymphocytes [59; 135; 148-151] that in some cases were also present in 
MCI patients, suggesting that oxidative stress may represent an early event in the 
pathogenesis of AD.  One of these studies also pointed out the correlation of the higher 
levels of oxidative DNA damage in peripheral lymphocytes with lower plasma levels of 
antioxidants [150]. Lower plasma antioxidants have been also described by other groups 
[152-154], together with lower levels of glutathione in lymphocytes of patients with 
familial AD [155].  
Increased lipid and protein oxidative damage have also been found in mitochondria 
isolated from patients with AD [156]. These results were in agreement with the 
increased lipid peroxidation products found in lymphocytes from patients with the 
familial form of AD, carrying mutations in amyloid protein precursor (APP) or 
presinilin 1 (PS1) genes [157] and in the PS1M146L transgenic mice model of AD 
[158]. In addition, a recent study pointed out the increased susceptibility of AD 
lymphoblasts to cell death induced by H2O2 compared to healthy controls [136]. 
Several studies in AD lymphocytes have suggested the involvement of p53 signaling in 
the pathogenesis of AD, due to its role in the response to DNA damage and in cell cycle 
control [40; 52; 159; 160]. Buizza and coworkers found that oxidative imbalance altered 
the conformation of p53 protein in lymphocytes from AD patients. They suggested that 
the oxidation of the p53 could make the protein dysfunctional and represent an early 
marker of oxidative alterations [161]. 
 It is worth to highlight that lymphocytes from AD patients represent a useful tool to test 
the effect of mitochondrial-related therapeutic approaches for AD. The cholinesterase 
inhibitor rivastigmine, already in use for AD, has been shown to enhance the 
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mitochondrial electron transport chain in lymphocytes from AD patients [162], and 
galantamine or melatonin treatments appear to protect AD lymphocytes from cell 
oxidative damage [163; 164]. In addition, peripheral measures of mitochondrial 
dysfunction might be helpful in developing biomarkers to combat AD [165; 166]. 
Alterations in the UPS activity in the CNS and peripheral cells from AD patients might 
also have detrimental consequences for cell survival [167; 168]. In the AD brain 
changes in the UPS have been linked to the accumulation of neurofibrillary tangles 
[169], and it has been reported that ubiquitin mediates A! neurotoxicity-inducing 
apoptosis [170].    
Changes in the proteasome activity have been observed in peripheral tissues including 
increased levels of ubiquitin in cerebrospinal fluid (CSF) of AD patients [171] and a 
reduction in proteasome activity in CD45 T-lymphocytes from the elderly [172]. Work 
in our laboratory demonstrated selective impaired degradation in the UPS of key 
proteins involved in the Ca2+/CaM-dependent regulation of survival/death of 
lymphoblasts from AD patients. First, we found that CaM itself is degraded at a lower 
rate in AD lymphoblasts than in control cells, allowing the accumulation of the protein 
in AD cells [59]. The impaired CaM degradation in AD lymphoblasts was associated 
with higher basal ROS levels when compared with control cells. Treatment of 
lymphoblasts with antioxidants like glutathione (GSH) or trolox reduced ROS levels 
and restored CaM degradation rate [59]. By contrast, the UPS-dependent degradation of 
the CDK inhibitors p27 and p21 is enhanced in AD cells [53; 173]. The altered rate of 
degradation of these proteins does not appear to be the result of nonspecific alteration of 
general protein degradation in lymphoblasts from AD cells in consonance with reports 
from other groups [174; 175]. Nevertheless, the ubiquitin-protein ligase system seems 
to be affected in PBMCs from AD patients, although they don’t show significant 
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reduction in global proteasome activity [175]. It was proposed that the determination of 
two of these ubiquitin-ligases, E1 and E2, in combination with other blood-cell markers 
may be useful as biomarkers for AD diagnosis [175]. 
The activation of the NF-"B transcription factor depends on the degradation in the UPS 
of the associated inhibitory molecule of the I"B family [176]. Besides its widely known 
role in inflammation and immune responses, NF-"B is involved in the control of cell 
division and apoptosis [177; 178]. Postmortem brain tissues from AD patients have 
revealed altered NF-"B activity in cells in the vicinity of amyloid plaques [179]. 
Moreover, it has been shown that conditioned medium from A!-stimulated glial cells 
triggers neuronal cell division [180], suggesting that the inflammatory process may be 
one of the mitotic pressures in AD. Deregulated NF-"B activity has been reported in 
PBMCs and lymphoblasts from AD patients associated with changes in cell survival 
[50; 51]. On the other hand, enhanced UPS-dependent degradation of I"B appears to 
underlie the beneficial effects of anti-inflammatory molecules in AD [181]. 
Role of altered lymphocytes response in AD pathogenesis 
Apart from the molecular alterations observed in lymphocytes derived from AD patients 
in relation to the mechanisms involved in the control of cell survival/death described 
above, a large body of evidence indicates the existence of other alterations in systemic 
immune responses in AD. Changes in lymphocyte and macrophage distribution together 
with the presence of autoantibodies, inflammatory factors and cytokine production have 
been described in AD patients [8; 9; 182-189]. Moreover increased expression of Toll-
like receptor 2 and 4 (TLR2, TLR4) have been found on PBMCs from AD patients 
[190]. It is believed that both TLRs are involved in neuroinflammation, due to their 
ability to bind amyloid-! [191]. In addition, global approaches such as microarray 
analysis of PBMCs and lymphocytes from AD patients show a prominent gene 
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deregulation when compared to age-matched controls [16; 17]. Changes in patterns of 
immune mediators in the periphery have been linked to AD and were used to predict 
disease progression [192].   
 However, despite the evidence for the existence of a communication between the CNS 
and the immune system, the involvement of immune alteration in the instigation and/or 
progression of AD is far from being completely understood. 
Functional integrity of the immune system has been linked to the functional integrity of 
the brain [193]. It was shown for example that immunocompromised mice display 
impaired hippocampal functions [194], and the cognitive alterations associated with the 
immune deficiencies could be rescued by immunomodulation [195; 196].  On the other 
hand, it was reported that, the triple-transgenic mouse (3xTg-AD), show premature 
immunosenescence [197]. 3xTg-AD mouse, which harbors APPSwe and tauP301L 
transgenes on a mutant Long-chain ceramide is elevated in presenilin 1 (PS1M146V) 
knock-in background, develops both A! plaques and neurofibrillary tangles with a 
temporal- and regional-specific profile that closely mimics their development in the 
human AD brain [198]. Taken together, these studies suggest that circulating immune 
cells play an essential role in brain function and support the involvement of systemic 
immunity and inflammation in behavioral and cognitive deficits, such as those in AD. 
In other words, the immune cells present in the CNS may have neuroprotective effects. 
However, accumulation of immune cells in brain areas or uncontrolled cell response 
could eventually increase the oxidative and inflammatory processes and contribute to 
the instigation or progression of neurodegeneration [199].  Apparently acute activation 
of the circulating immune cells within the CNS has different consequences for the 
young and aged/or diseased brain. In the latter conditions, systemic inflammation 
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impacts on resident microglia to adopt a more aggressive phenotype with the enhanced 
synthesis of pro-inflammatory mediators. 
On the other hand, abnormalities found in circulating immune cells could be the 
downstream result of AD processes leading to a deficient control of peripheral 
processes. The brain regulates key biological processes throughout the organism by 
releasing molecules into the blood and CSF. Proteins, such as amyloid-!, or 
inflammatory mediators from the CNS may cause systemic immune reaction. Therefore, 
communication between the CNS and the immune system in AD could thus influence 
both the lymphocyte distribution in the blood and the production of immune mediators 
[15; 200]. PBMCs from AD patients show increased production of several cytokines, 
chemokines, as well as increased expression of growth factors and chemokine receptors, 
after in vitro stimulation by A! [188]. Amyloid-! was reported to stimulate the 
proliferative response of lymphocytes from AD patients [201]. Cytokines, chemokines, 
and growth factors regulate diverse cellular processes, including proliferation and 
survival, and they are important for the development and function of the hematopoietic 
and nervous systems. In Fig. 1 we have summarized schematically the bidirectional 
communication between the CNS and the immune system, highlighting the reported 
changes in lymphocytes signaling. 
The possibility should also be considered that both changes in the CNS and systemic 
alterations share common underlying etiological processes. AD has been proposed to be 
a multifactorial disease that affects both CNS and systemic processes [202]. Most 
likely, there is no a single trigger that could explain AD etiology, but several 
interconnected processes, that together with genetic risk factors, determine the clinical 
manifestations of dementia.  
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Concluding Remarks 
The studies summarized here suggest that AD is accompanied by changes in peripheral 
cells, particularly those in the immune system. Changes that occur in lymphocytes from 
AD subjects include cell cycle deregulation, alterations in cell viability, proliferation, 
apoptosis, oxidative metabolism, proteasome activity, calcium homeostasis, and cellular 
signal transduction systems. At present it is not possible to conclude whether immune 
changes play a significant role in the development of cognitive decline, or by contrast 
they are downstream consequence of brain pathology. Nonetheless, evaluation of 
systemic alterations may be useful to further characterize immune dysfunction during 
disease progression, and their influence on AD pathology. On the other hand, because 
of their easy accessibility, peripheral cells may be of great importance for identification 
of biological markers of AD, and a suitable platform for monitoring the efficiency of 
novel therapies. 
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Legend to Figure 1 
 
 
Figure 1 
 
Communication between the CNS and the immune system: Changes in signaling 
pathways in AD lymphocytes. 
 
As the consequence of chronic neuroinflammation and neurodegeneration, A! peptides 
and pro-inflammatory mediators can reach the blood through altered BBB. The CNS-
derived molecules could then induce changes in key signaling pathways that control the 
survival/death lymphocyte’s fate. Conversely, increased production of cytokines and 
chemokines by activated lymphocytes may impact the CNS contributing to exacerbate 
the neuroimflammation. Robust arrows denote reported activation in lymphocytes 
derived from AD patients. 
 

